ImmunoPET imaging for detecting malignant cancers
CD70-targeted PET/ CT in the Diagnosis of Malignant Cancers
PHASE2 · RenJi Hospital · NCT06852638
This study is testing a new imaging method to see if it can better detect certain types of cancer in patients who have or might have these diseases.
Quick facts
| Phase | PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | RenJi Hospital (other) |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT06852638 on ClinicalTrials.gov |
What this trial studies
This study focuses on optimizing a new imaging technique called CD70-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) to evaluate its effectiveness in diagnosing malignant cancers such as renal cancer, lymphoma, and nasopharyngeal carcinoma. Patients with confirmed or suspected malignancies will undergo whole-body scans after receiving a tracer injection, and the imaging results will be quantitatively analyzed. The study aims to compare the diagnostic efficacy of this new imaging method against conventional imaging techniques.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18-80 with confirmed or suspected renal cancer, lymphoma, or nasopharyngeal carcinoma.
Not a fit: Patients who are pregnant or have severe hepatic and renal insufficiency may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the accuracy of cancer diagnosis and treatment monitoring for patients.
How similar studies have performed: While this approach is innovative, similar imaging techniques have shown promise in other studies, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18-80 year-old and of either sex； * Histologically confirmed diagnosis of renal cancer (especially ccRCC)/lymphoma/NPC or suspected renal cancer/lymphoma/NPC by diagnostic imaging; * Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol. Exclusion Criteria: * Pregnancy； * Severe hepatic and renal insufficiency; * Allergic to single-domain antibody radiopharmaceuticals.
Where this trial is running
Shanghai
- Renji Hospital, School of Medicine, Shanghai Jiao Tong University — Shanghai, China (RECRUITING)
Study contacts
- Principal investigator: Weijun Wei, Ph.D. & M.D. — Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
- Study coordinator: Weijun Wei, Ph.D. & M.D.
- Email: wwei@shsmu.edu.cn
- Phone: 15000083153
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Renal Cancer, Renal Clear Cell Carcinoma, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma, Mantle Cell Lymphoma, Nasopharyngeal Carcinoma, The cluster of differentiation